Freshworks Executive Sold Over: Is FRSH Stock a Buy?
An insider stake moved when a Freshworks executive sold over 32,577 shares for roughly $275,000. This article breaks ...
Which Cash Back Cards Have No Annual Fee
Uncover which cash back cards come with no annual fee. Choose the best option for your spending habits!
27,852 articlesInvested $1,000 These 2016 IPOs: Where They Stand Now
A look at five 2016 IPOs shows how a $1,000 investment in each would have fared through 2026, highlighting divergent ...
Morning Minute: Bitcoin Outperforms Stocks and Gold
When markets tremble, Bitcoin often steps into the spotlight. This morning minute explores why BTC can outperform tra...
Buffett Bets on Moats in 2026; Your Portfolio Faces Slippage
Midyear market shifts put Buffett's moat concept under stress as MOAT slips while the broad market climbs. Here’s wha...
Can Apple Stock Reach $400 This Year? Three Catalysts at Work
Apple stock is trading in the high 300s as traders weigh a possible rally. Here are three catalysts that could push a...
Beaten-Down Consumer Stocks July: 3 Names to Watch
Market mood slides while retail spend stays resilient. Three beaten-down consumer stocks july look poised for catalys...
Cramer Says Right Now IBM Buzz Grows Amid Valuation Debate
IBM is attracting fresh investor attention as its AI infrastructure strategy gains traction. Arvind Krishna’s reshape...
Netflix Sinks Soft Guidance as Shares Slump on Q3 Outlook
Shares moved lower after Netflix issued a softer-than-expected Q3 outlook, prompting a wave of questions about growth...
Ethereum Staking Address Holds Half Supply, Sparks Debate
The ethereum staking address holds about half of ETH in circulation, a milestone that highlights how staking and burn...
This Small-Cap Manager Just Sold Its Stake, Investors
When a notable small-cap manager exits a large stake in a data-security firm, it creates questions for investors. Thi...
Stocks Double Right: Top Growth Picks for 2026 Investing
Markets swing, but smart investors seek durable growth. This article highlights three names with a credible path to m...
Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status